MA53675A - Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret - Google Patents

Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret

Info

Publication number
MA53675A
MA53675A MA053675A MA53675A MA53675A MA 53675 A MA53675 A MA 53675A MA 053675 A MA053675 A MA 053675A MA 53675 A MA53675 A MA 53675A MA 53675 A MA53675 A MA 53675A
Authority
MA
Morocco
Prior art keywords
pyrazolo
kinase inhibitors
substituted compounds
ret kinase
pyridine substituted
Prior art date
Application number
MA053675A
Other languages
English (en)
Inventor
Steven W Andrews
Sean Aronow
James F Blake
Barbara J Brandhuber
Adam Cook
Julia Haas
Yutong Jiang
Gabrielle R Kolakowski
Elizabeth A Mcfaddin
Megan L Mckenney
Oren T Mcnulty
Andrew T Metcalf
David A Moreno
Li Ren
Tony P Tang
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MA53675A publication Critical patent/MA53675A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyridine Compounds (AREA)
MA053675A 2016-10-10 2017-10-10 Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret MA53675A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662406252P 2016-10-10 2016-10-10
US201762447850P 2017-01-18 2017-01-18
US201762491164P 2017-04-27 2017-04-27
US201762554817P 2017-09-06 2017-09-06
US201762566093P 2017-09-29 2017-09-29

Publications (1)

Publication Number Publication Date
MA53675A true MA53675A (fr) 2021-11-17

Family

ID=60153575

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053675A MA53675A (fr) 2016-10-10 2017-10-10 Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret

Country Status (39)

Country Link
US (8) US10112942B2 (fr)
EP (2) EP3523301B1 (fr)
JP (6) JP6776446B2 (fr)
KR (1) KR102143899B1 (fr)
CN (2) CN114163437B (fr)
AU (1) AU2017342022B2 (fr)
BR (1) BR112019007144B8 (fr)
CA (1) CA3039760C (fr)
CL (1) CL2019000941A1 (fr)
CO (1) CO2019004650A2 (fr)
CR (1) CR20190218A (fr)
CY (1) CY1123201T1 (fr)
DK (1) DK3523301T3 (fr)
DO (1) DOP2019000090A (fr)
EC (1) ECSP19032676A (fr)
ES (1) ES2805087T3 (fr)
HR (1) HRP20201008T1 (fr)
HU (1) HUE051424T2 (fr)
IL (2) IL265916B (fr)
JO (1) JOP20190076B1 (fr)
LT (1) LT3523301T (fr)
MA (1) MA53675A (fr)
MD (1) MD3523301T2 (fr)
MX (2) MX376465B (fr)
MY (1) MY195573A (fr)
NZ (1) NZ752793A (fr)
PE (1) PE20190918A1 (fr)
PH (1) PH12019500775A1 (fr)
PL (1) PL3523301T3 (fr)
PT (1) PT3523301T (fr)
RS (1) RS60536B1 (fr)
SA (1) SA519401541B1 (fr)
SG (1) SG11201903144PA (fr)
SI (1) SI3523301T1 (fr)
TN (1) TN2019000110A1 (fr)
TW (1) TWI704148B (fr)
UA (1) UA125030C2 (fr)
WO (1) WO2018071447A1 (fr)
ZA (1) ZA202004040B (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700372T1 (it) 2010-05-20 2017-09-07 Array Biopharma Inc Composti macrociclici come inibitori di trk chinasi
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
HRP20210177T1 (hr) 2015-07-16 2021-03-19 Array Biopharma, Inc. Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
CA3003721C (fr) 2015-11-02 2024-02-06 Blueprint Medicines Corporation Inhibiteurs de ret pour le traitement du cancer
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI876442B (zh) * 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI783057B (zh) 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
TWI791053B (zh) * 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3087972C (fr) 2018-01-18 2023-01-10 Array Biopharma Inc. Composes de pyrazolyl[4,3-c]pyridine substitues utilises en tant qu'inhibiteurs de la kinase ret
CN111971286B (zh) * 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
CA3096043A1 (fr) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Inhibiteur de ret destine a etre utilise dans le traitement du cancer presentant une alteration du ret
CN108658981A (zh) * 2018-06-01 2018-10-16 成都福柯斯医药技术有限公司 一种6-溴-4-甲氧基氢-吡唑[1,5-a]吡啶-3-甲腈的合成方法
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
US20220041588A1 (en) * 2018-09-27 2022-02-10 Fochon Pharmaceuticals, Ltd. Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors
EP3845531A4 (fr) * 2018-09-30 2021-11-24 Applied Pharmaceutical Science, Inc. Dérivé cyclique condensé à un pyrazole substitué, son procédé de préparation et application associée
WO2020114388A1 (fr) 2018-12-06 2020-06-11 深圳市塔吉瑞生物医药有限公司 Composé pyrazolo[1,5-a]pyridine substitué, composition le contenant et utilisation associée
KR20210100155A (ko) * 2018-12-07 2021-08-13 선샤인 레이크 파르마 컴퍼니 리미티드 Ret 억제제, 이의 약학 조성물 및 용도
US12209085B2 (en) 2018-12-07 2025-01-28 Sunshine Lake Pharma Co., Ltd. RET inhibitors, pharmaceutical compositions and uses thereof
US20220144847A1 (en) * 2019-02-19 2022-05-12 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
CN111635400A (zh) 2019-03-02 2020-09-08 察略盛医药科技(上海)有限公司 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
EP3950685A4 (fr) * 2019-04-03 2022-12-14 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory Composé de pyrazolopyridine utilisé comme inhibiteur de ret et son application
WO2020207941A1 (fr) * 2019-04-09 2020-10-15 F. Hoffmann-La Roche Ag Composés hétérocycliques en tant qu'inhibiteurs de la monoacylglycérol lipase (magl)
AU2020276802B2 (en) * 2019-05-14 2025-08-28 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing bicyclic derivative, preparation method therefor and use thereof
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
WO2020248972A1 (fr) * 2019-06-10 2020-12-17 Js Innopharm (Shanghai) Ltd Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinase, compositions comprenant le composé hétérocyclique, et leurs procédés d'utilisation
GB201908511D0 (en) 2019-06-13 2019-07-31 Adorx Therapeutics Ltd Hydroxamate compounds
US11666570B2 (en) * 2019-07-11 2023-06-06 The Board Of Trustees Of The Leland Stanford Junior University Diagnosis and regulation of epidermal differentiation and cancer cell activity
CN114072404B (zh) * 2019-07-12 2023-09-15 首药控股(北京)股份有限公司 Ret选择性抑制剂及其制备方法和用途
WO2021023209A1 (fr) 2019-08-05 2021-02-11 北京志健金瑞生物医药科技有限公司 Composés à cycles fusionnés polycycliques contenant de l'azote, composition pharmaceutique associée, leur procédé de préparation et leur utilisation
WO2021043209A1 (fr) * 2019-09-04 2021-03-11 广东东阳光药业有限公司 Inhibiteur de ret, composition pharmaceutique et utilisation associée
CN112574236B (zh) * 2019-09-29 2024-08-09 广东东阳光药业股份有限公司 一种ret抑制剂、其药物组合物及其用途
CN112574235B (zh) * 2019-09-29 2024-01-16 广东东阳光药业股份有限公司 一种ret抑制剂、其药物组合物及其用途
WO2021089791A1 (fr) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021088911A1 (fr) * 2019-11-08 2021-05-14 杭州邦顺制药有限公司 Dérivé de 3,6-diazabicyclo[3.1.1]heptane utilisé en tant qu'inhibiteur de kinase ret
CN112851664B (zh) * 2019-11-12 2024-03-29 浙江海正药业股份有限公司 吡唑[1,5-a]吡啶-3-腈化合物及其在医药上的用途
CN112939967B (zh) * 2019-12-11 2024-08-27 深圳众格生物科技有限公司 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN111004257B (zh) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 制备RET抑制剂Selpercatinib的方法
AU2020410900B2 (en) * 2019-12-27 2024-06-13 Tyk Medicines, Inc. Compound used as RET kinase inhibitor and application thereof
CN113121524B (zh) * 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN111269229B (zh) * 2020-03-27 2021-02-12 苏州信诺维医药科技有限公司 一种治疗癌症的化合物
CN111410662B (zh) * 2020-03-27 2020-12-29 苏州信诺维医药科技有限公司 一种酪氨酸激酶抑制剂
CN111233899B (zh) * 2020-03-27 2020-12-29 苏州信诺维医药科技有限公司 一种ret抑制剂
CN111285887B (zh) * 2020-03-27 2020-11-17 苏州信诺维医药科技有限公司 一种螺环化合物
CN113527292B (zh) * 2020-04-13 2025-07-22 广东东阳光药业股份有限公司 一种ret抑制剂、其药物组合物及其用途
CN113527291B (zh) * 2020-04-13 2025-07-22 广东东阳光药业股份有限公司 Ret抑制剂、其药物组合物及其用途
CN113527290B (zh) * 2020-04-13 2025-07-22 广东东阳光药业股份有限公司 一种ret抑制剂、其药物组合物及其用途
TWI865765B (zh) * 2020-04-17 2024-12-11 美商絡速藥業公司 結晶ret抑制劑
CN113620945B (zh) * 2020-05-07 2024-08-23 广东东阳光药业股份有限公司 Ret抑制剂、其药物组合物及其在药物中的应用
JP2023527412A (ja) 2020-05-29 2023-06-28 ブループリント メディシンズ コーポレイション プラルセチニブの固体形態
CN113880865A (zh) * 2020-07-01 2022-01-04 上海艾力斯医药科技股份有限公司 吡唑[1,5-a]吡啶类化合物及其制备方法与应用
WO2022020279A1 (fr) 2020-07-21 2022-01-27 Teva Pharmaceuticals International Gmbh Formes à l'état solide de selpercatinib et leur procédé de préparation
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
JP7564942B2 (ja) * 2020-08-20 2024-10-09 チャンスー チア タイ フェンハイ ファーマシューティカル カンパニー リミテッド Ｒｅｔキナーゼ阻害剤としてのヘテロ芳香族環化合物及びその製造と使用
US20230321098A1 (en) 2020-08-25 2023-10-12 Loxo Oncology, Inc. Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers
CN114249724B (zh) * 2020-09-25 2023-05-26 鲁南制药集团股份有限公司 一种唑吡坦中间体的制备方法
WO2022069357A1 (fr) 2020-10-01 2022-04-07 Sandoz Ag Forme cristalline du selpercatinib
WO2022100738A1 (fr) * 2020-11-13 2022-05-19 上海翰森生物医药科技有限公司 Forme cristalline d'une base libre d'inhibiteur contenant un dérivé à noyau bicyclique, procédé de préparation et utilisation de la forme cristalline
CN114478586A (zh) * 2020-11-13 2022-05-13 上海翰森生物医药科技有限公司 一种含二并环类衍生物抑制剂盐或晶型及其制备方法和应用
CN114621256A (zh) * 2020-12-11 2022-06-14 深圳众格生物科技有限公司 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
TW202237118A (zh) 2020-12-14 2022-10-01 美商絡速藥業公司 用於預防腦轉移之組合物及方法
AU2021402927A1 (en) 2020-12-18 2023-06-29 Loxo Oncology, Inc. Ret inhibitor combination therapy for treating cancer
TW202237086A (zh) 2020-12-18 2022-10-01 美商絡速藥業公司 以ret抑制劑及鉑劑治療癌症之方法
TWI818424B (zh) * 2021-02-08 2023-10-11 大陸商北京志健金瑞生物醫藥科技有限公司 含氮多環稠環類化合物，其藥物組合物、製備方法和用途
CN113321668A (zh) * 2021-06-21 2021-08-31 江苏慧聚药业有限公司 塞尔帕替尼的合成
CN115594678B (zh) * 2021-07-09 2024-11-15 北京志健金瑞生物医药科技有限公司 含氮多环稠环类化合物的制备方法及其中间体和用途
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物
AU2022463015A1 (en) 2021-10-22 2024-05-09 Tract Pharmaceuticals, Inc. Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CA3238202A1 (fr) 2021-12-13 2023-06-22 Loxo Oncology, Inc. Procedes de preparation de la forme cristalline a du selpercatinib, inhibiteur de ret
CN119998285A (zh) * 2022-08-03 2025-05-13 百时美施贵宝公司 用于调控ret蛋白的化合物
EP4578458A1 (fr) 2022-08-24 2025-07-02 Toray Industries, Inc. Médicament pour traitement et/ou prévention du cancer
CN117229292B (zh) * 2022-10-18 2025-08-15 药雅科技(上海)有限公司 Ret抑制剂的制备及其应用
TW202504611A (zh) 2023-03-30 2025-02-01 美商銳新醫藥公司 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
WO2025034702A1 (fr) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
CN119504796A (zh) * 2024-11-20 2025-02-25 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用

Family Cites Families (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
CA2253871C (fr) 1996-05-08 2005-04-26 Biogen, Inc. Ligand ret (retl) pour stimuler la croissance renale et neuronale
US6682921B1 (en) 1996-08-21 2004-01-27 New York University Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
AU7103900A (en) 1999-09-01 2001-03-26 Biogen, Inc. Ret ligand 5 (retl5) compositions and uses thereof
FI20000403A0 (fi) 2000-02-22 2000-02-22 Hannu Sariola GDNF perhesukuisten yhdisteiden käyttö kivessyövän hoitoon tarkoitettujen tuotteiden valmistamiseksi
BR0112272A (pt) 2000-06-22 2003-05-06 Genentech Inc Anticorpo monoclonal anti-trkc agonista, cadeia pesada de anticorpo anti-trkc, cadeia leve de anticorpo anti-trkc, cadeia pesada de anticorpo anti-trkc murino, cadeia pesada de anticorpo anti-trkc humano, anticorpo agonista anti-trkc murino, anticorpo agonista anti-trkc humano, moléculas de ácido nucléico isolado, moléculas de ácido nucléico, vetor, linhagens de células hospedeiras, linhagens de células de hibridoma, célula hospedeira, polipeptìdeo, composição farmacêutica, método para o tratamento de neuropatia ou doença neurodegenerativa ou reparo de uma célula nervosa lesionada, método para aumentar a proliferação, manutenção ou regeneração de neurÈnios periféricos, método para o tratamento de doença ou condição que envolve a degeneração celular em um paciente mamìfero, método de indução de angiogênese, método de fabricação de um anticorpo anti-trkc, usos de um anticorpo
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US7466344B2 (en) 2002-06-07 2008-12-16 Scimeasure Analytical Systems, Inc. High-speed low noise CCD controller
ITMI20021620A1 (it) 2002-07-23 2004-01-23 Novuspharma Spa Composto ad ativita' antitumorale
CA2493000A1 (fr) 2002-07-24 2004-01-29 University Of Cincinnati 4-(4-methylpiperazin-1-ylmethyl)-n-[4 methyl-3-(4-pyridin-3yl)pyrimidin-2-ylamino)phenyl] benzamide utilise pour le traitement des maladies associees a une kinase ret mutee
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
JP2005106669A (ja) 2003-09-30 2005-04-21 Olympus Corp 生体関連物質の反応・測定システム
US20090143399A1 (en) 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
CA2543116A1 (fr) 2003-10-27 2005-05-19 Genelabs Technologies, Inc. Procedes de preparation de derives 7-(2'-.szlig.-d-ribofuranosyl substitue)-4-(nr2r3)-5-(ethyn-1-yl substitue)-pyrrolo[2,3-d]pyrimidine
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
CN1902200A (zh) 2003-11-21 2007-01-24 诺瓦提斯公司 用做蛋白激酶抑制剂的1h－咪唑并喹啉类衍生物
AR047496A1 (es) 2003-11-28 2006-01-25 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
WO2005062795A2 (fr) 2003-12-19 2005-07-14 Plexxikon, Inc. Composes et methodes de developpement de modulateurs de ret
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
WO2005068424A1 (fr) 2004-01-20 2005-07-28 Cell Therapeutics Europe S.R.L. Derives d'indolinone en tant qu'inhibiteurs de tyrosine kinase de recepteurs
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
WO2005099363A2 (fr) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methodes de diagnostic, de prevention et de traitement de metastases cancereuses
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CA2575808A1 (fr) 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Composes a base de pyrrolopyrimidine a substitution arylamine inhibiteurs de kinases multiples
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
EP1848506A2 (fr) 2005-02-18 2007-10-31 Attenuon, LLC Derives de diazepine fusionnes pyrimidine et pteridines fusionnees indole
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
CA2604787A1 (fr) 2005-04-15 2006-10-26 Cylene Pharmaceuticals, Inc. Analogues de quinobenzoxazines et procedes d'utilisation de ceux-ci
US20080287437A1 (en) 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
US20100047777A1 (en) 2005-05-26 2010-02-25 The Johns Hopkins University Methods for identifying mutations in coding and non-coding dna
CA2650999A1 (fr) 2005-05-31 2006-12-07 The Pfahl Family Trust (Dated 9 July 1996) Derives de biarylheterocycle substitues utilises comme inhibiteurs de la proteine kinase pour le traitement du cancer et d'autres maladies
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
NZ565255A (en) 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
BRPI0615277A2 (pt) 2005-08-25 2009-08-04 Creabilis Therapeutics Spa conjugado de polìmeros de k-252a, composição farmacêutica compreendendo o referido conjugado, bem como uso do mesmo
US7803806B2 (en) 2005-11-03 2010-09-28 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
EP1785420A1 (fr) 2005-11-14 2007-05-16 4Sc Ag Analogues de thiazole et leurs utilisation
US20070149523A1 (en) 2005-11-14 2007-06-28 Jan Ehlert Thiazole Analogues and Uses Thereof
WO2007057399A2 (fr) 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Traitement du cancer
WO2007057397A1 (fr) 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Traitement du cancer
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
WO2007065664A2 (fr) 2005-12-08 2007-06-14 Novartis Ag Acides pyrazolo[1,5-a]pyridine-3-carboxyliques utilises en tant qu’inhibiteurs de la ephb et vegfr2 kinase
JP5474354B2 (ja) 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007087245A2 (fr) 2006-01-24 2007-08-02 Merck & Co., Inc. Inhibition de la tyrosine kinase ret
AU2007209689B2 (en) 2006-01-27 2012-03-15 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
CN101563336A (zh) 2006-03-16 2009-10-21 诺瓦提斯公司 用于治疗特别是黑素瘤的杂环有机化合物
US7820657B2 (en) 2006-03-17 2010-10-26 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
US8263604B2 (en) 2006-03-27 2012-09-11 Nerviano Medical Sciences S.R.L. Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
CN101460175A (zh) 2006-05-15 2009-06-17 Irm责任有限公司 用于fgf受体激酶抑制剂的组合物和方法
US20090209580A1 (en) 2006-05-18 2009-08-20 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008031551A2 (fr) 2006-09-12 2008-03-20 Novartis Forschungsstiftung, Zweigniederlassung Traitement du cancer non neuroendocrinien
ES2565683T3 (es) 2006-09-15 2016-04-06 Xcovery, Inc. Compuestos inhibidores de quinasa
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
EP1918291A1 (fr) 2006-10-30 2008-05-07 Novartis AG Dérives de pyrazole fusionnes substitués de 3-aminocarbonyle comme modulateurs de protéine kinase
EP2099774A4 (fr) 2006-11-15 2010-11-24 Ym Biosciences Australia Pty L Inhibiteurs de l'activité kinase
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
CA2673736A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composes et procedes pour la modulation de kinases et indications pour celle-ci
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
US20080199426A1 (en) 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
EP2114403A2 (fr) 2007-01-19 2009-11-11 Bayer Healthcare, LLC Traitement de cancers présentant une résistance à des agents chimiothérapeutiques
US20080234267A1 (en) 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
US20110189167A1 (en) 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
WO2008137794A1 (fr) 2007-05-04 2008-11-13 Irm Llc Composés et compositions utiles en tant qu'inhibiteurs des kinases c-kit et pdgfr
WO2008138184A1 (fr) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
WO2009003136A1 (fr) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines substituées destinées au traitement de troubles de prolifération cellulaire
CA2692945A1 (fr) 2007-07-09 2009-01-15 Astrazeneca Ab Composes 945
US20100209488A1 (en) 2007-07-16 2010-08-19 The Regents Of The University Of California Protein kinase modulating compounds and methods for making and using them
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
NZ582708A (en) 2007-07-19 2012-04-27 Schering Corp Heterocyclic amide compounds as protein kinase inhibitors
PH12013501594A1 (en) 2007-07-20 2014-05-12 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
WO2009017838A2 (fr) 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
EP2185698B1 (fr) 2007-08-07 2015-04-22 Purdue Research Foundation Inhibiteurs de kinase et leurs utilisations
EP2025678A1 (fr) 2007-08-17 2009-02-18 Oncalis AG Composés pyrazolo[3,4-d]pyrimidine et leur utilisation comme modulateur de protein kinase
WO2009042646A1 (fr) 2007-09-24 2009-04-02 Curis, Inc. Agents antiprolifératifs
CA2703329A1 (fr) 2007-10-23 2009-04-30 Novartis Ag Utilisation d'anticorps trkb pour le traitement de troubles respiratoires
WO2009071480A2 (fr) 2007-12-04 2009-06-11 Nerviano Medical Sciences S.R.L. Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase
CN101459004B (zh) 2007-12-14 2011-02-09 深圳富泰宏精密工业有限公司 电子装置的按键面板结构及制造该按键面板结构的方法
CL2009000090A1 (es) 2008-01-17 2009-07-24 Irm Llc Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo.
JP2009203226A (ja) 2008-01-31 2009-09-10 Eisai R & D Management Co Ltd ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
WO2009103076A1 (fr) 2008-02-15 2009-08-20 Oxigene, Inc. Méthodes et compositions pour améliorer l'efficacité des inhibiteurs des récepteurs tyrosine kinases (rtk)
EP2966076A1 (fr) 2008-03-19 2016-01-13 ChemBridge Corporation Nouveaux inhibiteurs de la tyrosine kinase
WO2009118411A2 (fr) 2008-03-28 2009-10-01 Nerviano Medical Sciences S.R.L. Dérivés actifs de 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one en tant qu’inhibiteurs de kinase, procédé pour leur préparation et compositions pharmaceutiques les contenant
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
WO2009143018A2 (fr) 2008-05-19 2009-11-26 Plexxikon, Inc. Composés et procédés de modulation des kinases, et indications associées
GEP20125502B (en) 2008-05-23 2012-04-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
WO2009155052A1 (fr) * 2008-05-28 2009-12-23 Wyeth Composés de 1h-pyrrolo[2,3-b]pyridine substituée en position 3 et composés de 1h-pyrrolo[3,2-b]pyridine substituée en position 3, leur utilisation en tant qu’inhibiteurs de kinase mtor et pi3 kinase, et leur synthèses
JP5767965B2 (ja) 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
US20110212053A1 (en) 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
CA2730190A1 (fr) 2008-07-14 2010-01-21 Queen's University At Kingston Compositions pharmaceutiques contenant des inhibiteurs de ret et procedes de traitement du cancer
CN102105151B (zh) 2008-07-29 2013-12-18 内尔维阿诺医学科学有限公司 Cdk抑制剂在治疗神经胶质瘤中的应用
EP2352361B1 (fr) 2008-09-01 2014-09-24 Sharp Kabushiki Kaisha Panneau électroluminescent organique, affichage électroluminescent organique, éclairage électroluminescent organique et procédé de fabrication d un panneau, affichage et éclairage de ce genre
US20100075916A1 (en) 2008-09-05 2010-03-25 Auspex Pharmaceuticals, Inc. Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases
EP2161271A1 (fr) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Inhibiteurs d'alpha-carboline de NMP-ALK, RET, et Bcr-Abl
EP2376492B1 (fr) 2008-09-19 2015-04-08 Nerviano Medical Sciences S.r.l. Dérivés de 3,4-dihydro-2h-pyrrolo[1,2-a]pyrazine-1-one
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
DK2331530T3 (da) 2008-09-26 2013-11-11 Nat Health Research Institutes Kondenserede multicycliske forbindelser som proteinkinaseinhibitorer
BRPI0919873B8 (pt) 2008-10-22 2021-05-25 Array Biopharma Inc compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas
JP5686736B2 (ja) 2008-11-06 2015-03-18 アムビト ビオスシエンセス コルポラチオン プロテインキナーゼモジュレーターとしてのイミダゾロチアゾール化合物
WO2010058006A1 (fr) 2008-11-24 2010-05-27 Nerviano Medical Sciences S.R.L. Inhibiteur de cdk (kinase cycline-dépendante) pour le traitement d'un mésothéliome
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
WO2010111527A1 (fr) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines en tant qu'inhibiteurs de la kinase et leur utilisation médicale
US8492374B2 (en) 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
TWI484961B (zh) 2009-05-08 2015-05-21 Astellas Pharma Inc Diamine heterocyclic methyl ester compounds
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
EP2443117B1 (fr) 2009-06-15 2016-03-23 Nerviano Medical Sciences S.r.l. Dérivés de pyrimidinylpyrrolopyridinone substitués, procédé pour leur préparation et leur utilisation en tant qu'inhibiteurs de kinase
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
FR2951172B1 (fr) * 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
KR101147550B1 (ko) 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
KR101116756B1 (ko) 2009-10-27 2012-03-13 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물
CA2779105C (fr) 2009-10-29 2016-08-16 Hong Woo Kim Inhibiteurs de kinases
SG10201407453TA (en) 2009-11-13 2014-12-30 Genosco Kinase inhibitors
KR101094446B1 (ko) 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
ES2524576T3 (es) 2010-01-29 2014-12-10 Nerviano Medical Sciences S.R.L. Derivados de 6,7-dihidroimidazo[1,5-a]pirazin-8(5H)-ona como moduladores de proteína cinasa
WO2011093684A2 (fr) 2010-01-29 2011-08-04 Hanmi Holdings Co., Ltd. Dérivés thiéno[3,2-d]pyrimidines avec activité inhibitrice sur protéines kinases
JP2013519706A (ja) 2010-02-18 2013-05-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 癌転移を予防するための方法
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
SMT201700372T1 (it) 2010-05-20 2017-09-07 Array Biopharma Inc Composti macrociclici come inibitori di trk chinasi
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012037155A2 (fr) 2010-09-13 2012-03-22 Gtx, Inc. Inhibiteurs des tyrosines kinases
WO2012047017A2 (fr) 2010-10-05 2012-04-12 크리스탈지노믹스(주) Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant
JP2014005206A (ja) 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
ES2586588T3 (es) 2011-01-26 2016-10-17 Nerviano Medical Sciences S.R.L. Derivados tricíclicos, procedimiento para su preparación y su uso como inhibidores de quinasa
BR112013018515B1 (pt) 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
JP6013375B2 (ja) 2011-02-24 2016-10-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体
CN103492384B (zh) 2011-02-25 2016-05-11 诺华股份有限公司 作为trk抑制剂的化合物和组合物
WO2012135631A1 (fr) 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc 5-(pyrazin-2-yl)-1h-pyrazolo[3,4-b]pyridine substituée et dérivés de pyrazolo[3,4-b]pyridine en tant qu'inhibiteurs de protéine kinase
HUE046988T2 (hu) 2011-04-01 2020-04-28 Univ Utah Res Found Szubsztituált N-fenilpirimidin-2-amin analógok mint AXL kináz inhibitorok
US9284298B2 (en) 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
BR112013026137B1 (pt) 2011-04-19 2020-12-01 Nerviano Medical Sciences S.R.L pirimidinil-pirróis substituídos ativos como inibidores da quinase
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
MX342509B (es) 2011-05-12 2016-10-03 Nerviano Medical Sciences Srl Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
RU2606131C2 (ru) 2011-05-13 2017-01-10 Эррэй Биофарма Инк. СОЕДИНЕНИЯ ПИРРОЛИДИНИЛМОЧЕВИНЫ И ПИРРОЛИДИНИЛТИОМОЧЕВИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ TrkA
RU2477723C2 (ru) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
CN102827073A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013014039A1 (fr) 2011-07-28 2013-01-31 Nerviano Medical Sciences S.R.L. Pyrimidinyl-pyrroles substitués alcynyle agissant comme inhibiteurs de kinase
WO2013016720A2 (fr) 2011-07-28 2013-01-31 Gerinda Therapeutics, Inc. Nouveaux dérivés biaryl-hétérocycliques substitués en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer et d'autres maladies
CA2848369A1 (fr) 2011-08-04 2013-02-07 National Cancer Center Gene chimere de gene kif5b et de gene ret, et procede de determination de l'efficacite d'un traitement anticancereux ciblant le gene chimere
DK2748192T3 (en) 2011-08-23 2019-02-25 Found Medicine Inc KIF5B-RET-FUSION MOLECULES AND APPLICATIONS THEREOF
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
WO2013036232A2 (fr) 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Méthodes et compositions pouvant être utilisées en vue du traitement de maladies myéloprolifératives et d'autres maladies prolifératives
US8846712B2 (en) * 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013042137A1 (fr) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Hétérocycles bicycliques convenant comme inhibiteurs de l'irak4
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
JP6063945B2 (ja) 2011-10-07 2017-01-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としての４−アルキル置換３，４−ジヒドロピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン誘導体
ES2639064T3 (es) 2011-10-07 2017-10-25 Nerviano Medical Sciences S.R.L. Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa
AU2012339753A1 (en) 2011-11-14 2014-06-19 Tesaro, Inc. Modulating certain tyrosine kinases
TW201335372A (zh) 2011-11-30 2013-09-01 Nat Cancer Ct 誘導惡性幹細胞
RU2625799C2 (ru) 2011-12-30 2017-07-19 Ханми Фарм. Ко., Лтд. ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP2015109806A (ja) 2012-03-22 2015-06-18 アステラス製薬株式会社 新規ｒｅｔ融合体の検出法
ES2605388T3 (es) 2012-04-26 2017-03-14 Ono Pharmaceutical Co., Ltd. Compuesto inhibidor de Trk
WO2013170159A1 (fr) 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Traitement du cancer avec des composés inhibiteurs de hsp90
JP6231556B2 (ja) 2012-05-23 2017-11-15 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｎ−［５−（３，５−ジフルオロ−ベンジル）−１ｈ−インダゾール−３−イル］−４−（４−メチル−ピペラジン−１−イル）−２−（テトラヒドロ−ピラン−４−イルアミノ）−ベンズアミドの調製方法
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
PL2872491T3 (pl) 2012-07-11 2021-12-13 Blueprint Medicines Corporation Inhibitory receptora czynnika wzrostu fibroblastów
CN104619841A (zh) 2012-07-26 2015-05-13 日本国立癌症研究中心 Cep55基因与ret基因的融合基因
JP6276762B2 (ja) 2012-08-02 2018-02-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性な置換ピロール類
CN114129566A (zh) 2012-09-07 2022-03-04 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂
MX389105B (es) 2012-09-25 2025-03-20 Chugai Pharmaceutical Co Ltd Inhibidor de quinasas reordenadas durante la transfeccion (ret).
JP6326057B2 (ja) 2012-11-07 2018-05-16 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルおよびピリジニル−ピロロピリジノン、これらの調製のための方法、およびキナーゼ阻害剤としてのこれらの使用
BR112015010501A2 (pt) 2012-11-12 2017-07-11 Ignyta Inc composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada
WO2014078328A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-pyrrolidinyle, n'-pyrazolyl-urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
SG11201503731SA (en) 2012-11-13 2015-06-29 Array Biopharma Inc Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
WO2014078378A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-pyrrolidinyle urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078325A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-aryle monocycliques, n'-pyrazolyl-urée, thiourée, guanidine et cyanoguanidine utiles comme inhibiteurs de trka kinase
WO2014078331A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-(arylalkyle)-n'-pyrazolyle-urée, de thiourée, de guanidine et de cyanoguanidine en tant qu'inhibiteurs de la kinase trka
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078322A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de thiazolyl-urée, oxazolyl-urée, thio-urée, guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
WO2014078323A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-pyrrolidinyle, n'-pyrazolyl-urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
WO2014083567A2 (fr) 2012-11-29 2014-06-05 Yeda Research And Development Co. Ltd. Méthodes de prévention d'une métastase tumorale, de traitement et de pronostic du cancer, et d'identification d'agents susceptibles de constituer des inhibiteurs de métastase
WO2014086284A1 (fr) 2012-12-04 2014-06-12 上海医药集团股份有限公司 Composé de 3-cyanoquinoléine deutéré, composition pharmaceutique le comprenant, leur procédé de préparation et leur utilisation
FR3000492B1 (fr) 2012-12-28 2015-09-11 Oribase Pharma Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
FR3000493A1 (fr) 2012-12-28 2014-07-04 Oribase Pharma Nouveaux inhibiteurs de proteines kinases
CN104995184B (zh) 2012-12-28 2018-01-02 晶体基因技术株式会社 作为btk激酶抑制剂的2,3‑二氢异吲哚‑1‑酮诱导体与含此类的药学组合物
FR3000494B1 (fr) 2012-12-28 2015-08-21 Oribase Pharma Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
ES2710556T3 (es) 2013-02-19 2019-04-25 Ono Pharmaceutical Co Compuesto inhibidor de Trk
WO2014160524A1 (fr) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Effets cardiométaboliques et vasculaires de métabolites de glp-1
US8937071B2 (en) 2013-03-15 2015-01-20 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
EP3842424B1 (fr) * 2013-03-15 2024-12-11 The Trustees of Columbia University in the City of New York Modulateurs de map kinase et leurs utilisations dans le traitement de tauopathies
ES2616655T3 (es) 2013-03-15 2017-06-13 Glaxosmithkline Intellectual Property Development Limited Derivados de piridina como inhibidores de quinasa reorganizada durante la transfección (RET)
WO2014160521A1 (fr) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Dérivés de pipérazine et leur utilisation comme modulateurs de kit
WO2014184069A1 (fr) 2013-05-14 2014-11-20 Nerviano Medical Sciences S.R.L. Dérivés de 6-amino-7-désaza-purine, procédé pour les préparer et leur utilisation comme inhibiteurs de kinases
KR20160013028A (ko) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 그에 대한 적응증
WO2015017528A1 (fr) 2013-07-30 2015-02-05 Blueprint Medicines Corporation Fusions de pik3c2g
EP3628749A1 (fr) 2013-07-30 2020-04-01 Blueprint Medicines Corporation Fusions de ntrk2
US20150057335A1 (en) 2013-08-20 2015-02-26 National Cancer Center Novel fusion genes identified in lung cancer
CN105683182A (zh) 2013-08-30 2016-06-15 埃姆比特生物科学公司 联芳基乙酰胺化合物及其使用方法
WO2015058129A1 (fr) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Composés à utiliser pour traiter des troubles associés à l'enzyme kit
CA2926999C (fr) 2013-10-17 2021-10-19 Blueprint Medicines Corporation Derives de pyrrolo[2,1-f][1,2,4]triazine-4-yl)piperazine-1-yl) pyrimidinyle et compositions utiles pour le traitement de troubles associes a kit
EP3060560A1 (fr) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibiteurs du récepteur du facteur de croissance des fibroblastes
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US9801880B2 (en) 2013-12-02 2017-10-31 Bergenbio As Use of kinase inhibitors
WO2015108992A1 (fr) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Composés hétérobicycliques et leur utilisation en tant qu'inhibiteurs du récepteur fgfr4
RS59059B1 (sr) 2014-01-24 2019-08-30 Turning Point Therapeutics Inc Diaril makrociklična jedinjenja kao modulatori protein kinaza
EP3738952A1 (fr) 2014-02-14 2020-11-18 Exelixis, Inc. Formes solides cristallines du n-{4-[(6,7-diméthoxyquinolin-4-yl)oxy]phényl}-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
EP3132054B1 (fr) 2014-04-18 2021-06-30 Blueprint Medicines Corporation Fusions de met
EP3132056B1 (fr) 2014-04-18 2021-11-24 Blueprint Medicines Corporation Fusions de pik3ca
MA40434B1 (fr) 2014-05-15 2019-09-30 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka
EP3155118A1 (fr) 2014-06-10 2017-04-19 Blueprint Medicines Corporation Fusions de pkn1
WO2015191666A2 (fr) 2014-06-10 2015-12-17 Blueprint Medicines Corporation Fusions de raf1
WO2016011147A1 (fr) 2014-07-17 2016-01-21 Blueprint Medicines Corporation Fusions de prkc
CN105272930B (zh) 2014-07-17 2018-07-13 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
EP3169808B1 (fr) 2014-07-17 2019-05-22 Blueprint Medicines Corporation Fusion trio:tert dans le cancer
WO2016011141A1 (fr) 2014-07-17 2016-01-21 Blueprint Medicines Corporation Fusions de fgr
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
TWI560185B (en) 2014-08-18 2016-12-01 Ono Pharmaceutical Co Acid addition salt of trk inhibitor compound
RU2017111590A (ru) 2014-09-08 2018-10-10 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Кристаллические формы 2-(4-(4-этокси-6-оксо-1,6-дигидропиридин-3-ил)-2-фторфенил)-n-(5-(1,1,1-трифтор-2- метилпропан-2-ил)изоксазол-3-ил)ацетамида
WO2016037578A1 (fr) 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Nouveaux composés utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
MA40581A (fr) 2014-09-10 2019-04-10 Glaxosmithkline Ip Dev Ltd Dérivés pyridone utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
TWI538914B (zh) 2014-10-03 2016-06-21 國立交通大學 蛋白質激酶之選擇性抑制劑、其醫藥組成物及其用途
MX382607B (es) * 2014-11-14 2025-03-13 Nerviano Medical Sciences Srl Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa.
CA2967951C (fr) 2014-11-16 2023-11-07 Array Biopharma, Inc. Forme cristalline d'hydrogenosulfate de (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
WO2016081450A1 (fr) 2014-11-18 2016-05-26 Blueprint Medicines Corporation Fusions de prkacb
WO2016096709A1 (fr) 2014-12-16 2016-06-23 Eudendron S.R.L. Dérivés hétérocycliques modulant l'activité de certaines protéines kinases
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
KR101675984B1 (ko) 2015-02-23 2016-11-14 한양대학교 에리카산학협력단 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
US20180045727A1 (en) 2015-03-03 2018-02-15 Caris Mpi, Inc. Molecular profiling for cancer
US10364247B2 (en) 2015-04-21 2019-07-30 Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine Preparation and use of novel protein kinase inhibitors
GB201512365D0 (en) 2015-07-15 2015-08-19 King S College London Novel therapy
HRP20210177T1 (hr) 2015-07-16 2021-03-19 Array Biopharma, Inc. Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
EP3120851A1 (fr) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6- (2,6-dichlorophényl) -8-methyl-2-(phénylamino) -pyrido[2,3-d]pyrimidin-7-(8h)-one pour le traitement de cancers solides
KR101766194B1 (ko) 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
US10550124B2 (en) 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
WO2017049462A1 (fr) 2015-09-22 2017-03-30 合肥中科普瑞昇生物医药科技有限公司 Nouvel inhibiteur de la kinase flt3 et ses utilisations
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
CA3003721C (fr) 2015-11-02 2024-02-06 Blueprint Medicines Corporation Inhibiteurs de ret pour le traitement du cancer
WO2017097697A1 (fr) 2015-12-08 2017-06-15 Boehringer Ingelheim International Gmbh Procédé utilisant un gène de fusion ret comme biomarqueur pour sélectionner des patients atteints d'un cancer bronchique non à petites cellules (nsclc) et d'un cancer de la thyroïde pour un traitement anticancéreux
WO2017122815A1 (fr) 2016-01-15 2017-07-20 公益財団法人がん研究会 Nouveau fusant et son procédé de détection
TWI620748B (zh) 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
WO2017145050A1 (fr) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Dérivé de pyridylpyridone utile comme inhibiteur de la kinase ret dans le traitement du sci et du cancer
SG11201806930PA (en) 2016-02-23 2018-09-27 Taiho Pharmaceutical Co Ltd Novel condensed pyrimidine compound or salt thereof
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
IL297192A (en) 2016-04-15 2022-12-01 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
EP3442535B1 (fr) * 2016-04-15 2022-06-01 Cancer Research Technology Limited Composés hétérocycliques à utiliser en tant qu'inhibiteurs de kinases ret
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物

Also Published As

Publication number Publication date
US20180134702A1 (en) 2018-05-17
AU2017342022A1 (en) 2019-05-23
EP3523301B1 (fr) 2020-05-27
JP6776446B2 (ja) 2020-10-28
BR112019007144A2 (pt) 2018-04-19
MX376465B (es) 2025-03-07
JP7079303B2 (ja) 2022-06-01
HRP20201008T1 (hr) 2020-10-16
TW201825488A (zh) 2018-07-16
US20210186959A1 (en) 2021-06-24
IL265916A (en) 2019-06-30
JOP20190076A1 (ar) 2019-04-09
US10555944B2 (en) 2020-02-11
US10137124B2 (en) 2018-11-27
US20180133213A1 (en) 2018-05-17
US20180133200A1 (en) 2018-05-17
US10172851B2 (en) 2019-01-08
UA125030C2 (uk) 2021-12-29
IL277576B2 (en) 2023-05-01
JP2022062168A (ja) 2022-04-19
JOP20190076B1 (ar) 2023-03-28
LT3523301T (lt) 2020-07-27
ES2805087T3 (es) 2021-02-10
US20240066029A1 (en) 2024-02-29
ECSP19032676A (es) 2019-07-31
KR20190076976A (ko) 2019-07-02
CO2019004650A2 (es) 2019-05-21
JP2020503247A (ja) 2020-01-30
EP3523301A1 (fr) 2019-08-14
PT3523301T (pt) 2020-08-26
JP2023134580A (ja) 2023-09-27
DK3523301T3 (da) 2020-08-03
MX2020011250A (es) 2022-09-08
JP2022116108A (ja) 2022-08-09
JP7761732B2 (ja) 2025-10-28
WO2018071447A1 (fr) 2018-04-19
EP3753939A1 (fr) 2020-12-23
MY195573A (en) 2023-02-02
US20190183886A1 (en) 2019-06-20
PE20190918A1 (es) 2019-06-26
AU2017342022B2 (en) 2019-12-05
SA519401541B1 (ar) 2022-08-04
CA3039760C (fr) 2020-09-08
US10953005B1 (en) 2021-03-23
CN114163437B (zh) 2025-03-04
CL2019000941A1 (es) 2019-12-13
RS60536B1 (sr) 2020-08-31
ZA202004040B (en) 2023-01-25
US20230090520A1 (en) 2023-03-23
TWI704148B (zh) 2020-09-11
JP7502365B2 (ja) 2024-06-18
CN110382494A (zh) 2019-10-25
BR112019007144B8 (pt) 2022-01-25
CR20190218A (es) 2019-10-14
CA3039760A1 (fr) 2018-04-19
JP7311654B2 (ja) 2023-07-19
JP2025011247A (ja) 2025-01-23
MD3523301T2 (ro) 2020-11-30
NZ752793A (en) 2023-01-27
TN2019000110A1 (en) 2020-10-05
KR102143899B1 (ko) 2020-08-13
PH12019500775A1 (en) 2019-07-01
IL277576B1 (en) 2023-01-01
CY1123201T1 (el) 2021-10-29
CN110382494B (zh) 2021-11-16
DOP2019000090A (es) 2019-06-30
US10112942B2 (en) 2018-10-30
HUE051424T2 (hu) 2021-03-01
SI3523301T1 (sl) 2020-08-31
MX395444B (es) 2025-03-25
NZ792955A (en) 2025-02-28
CN114163437A (zh) 2022-03-11
IL265916B (en) 2020-11-30
US11998545B2 (en) 2024-06-04
SG11201903144PA (en) 2019-05-30
BR112019007144B1 (pt) 2020-07-14
JP7634606B2 (ja) 2025-02-21
JP2021035944A (ja) 2021-03-04
IL277576A (en) 2020-11-30
MX2019004205A (es) 2019-08-21
PL3523301T3 (pl) 2020-12-28

Similar Documents

Publication Publication Date Title
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
DK3523302T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
FR22C1006I2 (fr) Derives de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des janus kinases (jak)
ZA201800771B (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
LT3555097T (lt) Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
MA53487A (fr) Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
EP3345907A4 (fr) NOUVEAU COMPOSÉ PYRROLO[3,4-d]PYRIMIDINE OU SEL CORRESPONDANT
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
ME03672B (fr) 1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
EP3452481A4 (fr) Imidazo[1,2-b]pyridazines substituées, imidazo[1,5-b]pyridazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux
EP3328840A4 (fr) Composés bicycliques triazolo substitués en tant qu'inhibiteurs de pde2
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
EP3508487A4 (fr) COMPOSÉ DE PYRAZOLO [1,5-a]PYRIMIDINE
EP3666774A4 (fr) Composé 1h-pyrazolo[4,3-h]quinazoline servant en tant qu'inhibiteur de protéine kinase
EP3096762C0 (fr) Pyrazolo[1,5-a]pyrimidines comme composés antiviraux
EP3679042A4 (fr) Dérivés d'imidazo[1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta
MA46463A (fr) Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret
EP3330271A4 (fr) COMPOSÉ PYRROLO[2,3-d]PYRIMIDINE OU UN SEL DE CELUI-CI
TH1501006629A (th) อนุพันธ์พีร์โรโล[2,3-d]ไพริมิดีนในฐานะอะกอนิสต์ของ CB2 รีเซปเตอร์